Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.73 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | TPH1 | P17752 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12171366 | 0.85 | NPC1 (0.78) | NR1H4S1PR1NPC1RAB9AMAPT | |
| SCHEMBL1430178 | 0.85 | NR1H4 (0.68) | NR1H4S1PR1NPC1RAB9AMAPT | |
| SCHEMBL60692 | 0.85 | NR1H4 (0.68) | NR1H4S1PR1NPC1RAB9AMAPT | |
| SCHEMBL6697420 | 0.84 | NR1H4 (1.00) | NR1H4S1PR1NPC1RAB9AMAPT | |
| SCHEMBL7291752 | 0.84 | NR1H4 (1.00) | NR1H4S1PR1NPC1RAB9AMAPT | |
| SCHEMBL5207218 | 0.84 | MCHR1 (0.60) | NR1H4S1PR1 | |
| SCHEMBL12171136 | 0.84 | MCHR1 (0.60) | NR1H4S1PR1 | |
| SCHEMBL30850803 | 0.83 | NPC1 (0.62) | NR1H4S1PR1NPC1RAB9AMAPT | |
| SCHEMBL17612678 | 0.83 | NPC1 (0.71) | NR1H4NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL19131316 | 0.83 | NPC1 (0.71) | NR1H4NPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | claimed |
| EP-2300442-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | claimed |
| WO-2010008831-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-21 | — | — | WO | claimed |
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | disclosed |
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | disclosed |
| US-8362050-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-01-29 | — | — | US | disclosed |
| US-8362050-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-01-29 | — | — | US | disclosed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
| EP-2300442-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010008831-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | NR1H4 150/4885S1PR1 512/4885NPC1 856/4885 |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | NR1H4 150/4885S1PR1 512/4885NPC1 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.